Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Results of the Sickle Cell World Assessment Survey (SWAY) highlight the impact this debilitating disease has on patients and their families.
Novartis shares progress in advancing its industry-leading R&D pipeline. We are uniquely positioned to deliver transformational treatments through our scale, focus on innovative medicines, diverse range of therapeutic areas and exposure to cutting-edge platforms.
Novartis data at 2019 ASH and SABCS underscore our evolving R&D approach in innovative platforms to reimagine medicine and help improve patient outcomes.
New cell and gene manufacture in Stein offers hope for patients around the globe.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.
This site is intended for a global audience.